Breaking Finance News

Zacks Investment Research upgraded Novocure Ltd (NASDAQ:NVCR) to Hold in a report released today.

Zacks Investment Research has upgraded Novocure Ltd (NASDAQ:NVCR) to Hold in a report released on 9/29/2016.

Previously on 07/29/2016, Wedbush reported on Novocure Ltd (NASDAQ:NVCR) lowered the target price from $30.00 to $20.00. At the time, this indicated a possible upside of 1.66%.

Yesterday Novocure Ltd (NASDAQ:NVCR) traded 1.01% higher at $9.01. The company’s 50-day moving average is $8.20 and its 200-day moving average is $11.05. The last closing price is down -18.46% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 164,256 shares of the stock were exchanged, down from an average trading volume of 349,748

See Chart Below

Novocure Ltd (NASDAQ:NVCR)

Novocure Ltd has a 52 week low of $7.30 and a 52 week high of $30.89 The company’s market cap is currently $0.

General Information About Novocure Ltd (NASDAQ:NVCR)

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night. The Company has performed various pre-clinical research on TTFields and their effects in multiple solid tumor cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.